The effects of atypical and conventional antipsychotics on reduced processing speed and psychomotor slowing in schizophrenia: A cross-sectional exploratory study

Clinical Therapeutics

Volumn 30, Issue 4, 2008, Pages 684-692

  Morrens, Manuel ^a,b   Hulstijn, Wouter ^a,c   Sabbe, Bernard ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b PC St Norbertushuis   (Belgium)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

processing speed; psychomotor; schizophrenia; writing

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BROMPERIDOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; COPING BEHAVIOR; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE DURATION; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOMOTOR PERFORMANCE; SCHIZOPHRENIA; SYMPTOMATOLOGY; TASK PERFORMANCE; VERBAL MEMORY; WORKING MEMORY;

EID: 43549096636     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.04.012     Document Type: Article

References (32)

1. E Bleuler Dementia Praecox 1950 International Universities Press New York, NY
2. E Kraepelin Dementia Praecox and Paraphrenia 1971 Robert E. Krieger Pub Co New York, NY
3. MP Caligiuri JB Lohr DV Jeste Parkinsonism in neurolepticnaive schizophrenic patients Am J Psychiatry 150 1993 1343 1348
4. S Mohamed JS Paulsen D O'Leary Generalized cognitive deficits in schizophrenia: A study of first-episode patients Arch Gen Psychiatry 56 1999 749 754
5. EM Riley D McGovern D Mockler Neuropsychological functioning in first-episode psychosis-evidence of specific deficits Schizophr Res 43 2000 47 55
6. TA Niendam CE Bearden IM Rosso A prospective study of childhood neurocognitive functioning in schizophrenic patients and their siblings Am J Psychiatry 160 2003 2060 2062
7. M Morrens W Hulstijn B Sabbe Psychomotor slowing in schizophrenia Schizophr Bull 33 2007 1038 1053
8. D Wechsler Manual for the Wechsler Adult Intelligence Scale-Revised (WAIS-R) 1981 Psychological Corporation San Antonio, Tex
9. D Dickinson ME Ramsey JM Gold Overlooking the obvious: A meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia Arch Gen Psychiatry 64 2007 532 542
10. MA Lee K Jayathilake HY Meltzer A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia Schizophr Res 37 1999 1 11
11. L Kalra SH Jackson CG Swift Assessment of changes in psychomotor performance of elderly subjects Br J Clin Pharmacol 36 1993 383 389
12. KH Nuechterlein DM Barch JM Gold Identification of separable cognitive factors in schizophrenia Schizophr Res 72 2004 29 39
13. M Morrens E Wezenberg RJ Verkes Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration J Clin Psychopharmacol 27 2007 15 21
14. CD Frith The positive and negative symptoms of schizophrenia reflect impairments in the perception and initiation of action Psychological Med 17 1987 631 648
15. BJ Jogems-Kosterman FG Zitman JJ Van Hoof W Hulstijn Psychomotor slowing and planning deficits in schizophrenia Schizophr Res 48 2001 317 333
16. B Sabbe W Hulstijn J Van Hoof F Zitman Fine motor retardation and depression J Psychiatr Res 30 1996 295 306
17. G Pieters W Hulstijn W Vandereycken Fast psychomotor functioning in anorexia nervosa: Effect of weight restoration J Clin Exp Neuropsychol 27 2005 931 942
18. Diagnostic and Statistical Manual of Mental Disorders Fourth Edition 2000 American Psychiatric Association Washington, DC Text Revision
19. J Gerlach S Korsgaard P Clemmesen The St Hans Rating Scale for extrapyramidal syndromes: Reliability and validity Acta Psychiatr Scand 87 1993 244 252
20. The World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/e/policy/b3.htm. Accessed March 13, 2008.
21. SR Kay A Fiszbein LA Opler The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr Bull 13 1987 261 276
22. DC Delis JH Kramer E Kaplan BA Ober The California Verbal Learning Test (Manual) 1987 Psychological Corporation San Antonio, Tex
23. BA Cornblatt NJ Risch G Faris The Continuous Performance Test, identical pairs version (CPT-IP): I New findings about sustained attention in normal families Psychiatry Res 26 1988 223 238
24. O Spreen E Strauss A Compendium of Neuropsychological Tests: Administration, Norms and Commentary 1998 Oxford University Press New York, NY
25. M Morrens W Hulstijn J Van Hecke Sensorimotor and cognitive slowing in schizophrenia as measured by the Symbol Digit Substitution Test J Psychiatr Res 40 2006 200 206
26. KIKO Software Web site. http://www.kikosoft.com/products/wacom.php. Accessed March 13, 2008.
27. WP De Jong W Hulstijn BJ Kosterman BC Smits-Engelsman OASIS software and its application in experimental handwriting research ML Simner CG Leedham AJ Thomassen Handwriting and Drawing Research: Basic and Applied Issues 1996 IOS Press Amsterdam, The Netherlands
28. TE Goldberg RD Greenberg SJ Griffin The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia Br J Psychiatry 162 1993 43 48
29. RM Bilder RS Goldman J Volavka Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder Am J Psychiatry 159 2002 1018 1028
30. MF Green SR Marder SM Glynn The neurocognitive effects of low-dose haloperidol: A two-year comparison with risperidone Biol Pschiatry 51 2002 972 978
31. KS Hong JG Kim HJ Koh Effects of risperidone on information processing and attention in first-episode schizophrenia Schizophr Res 53 2002 7 16
32. ND Woodward SE Purdon HY Meltzer DH Zald A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia Int J Neuropsychopharmacol 8 2005 457 472